GenCure opened its pilot-scale facility in January 2018. This facility includes 2 clean rooms and a process development lab, compliant with FDA regulations and EU Annex 1.
The first phase of GenCure’s clinical-scale biomanufacturing facility opened in March 2020 in the heart of San Antonio, at the VelocityTX Innovation Center.
This facility includes an initial 6,700 square feet of clean-room production space, expandable to 14,000 square feet, and a 2,500-square-foot development lab, along with office and meeting space.
The biomanufacturing space is compliant with FDA regulations, EU Annex 1 and PMDA (Grade A, B, C, D).
Clean rooms are sized for a wide range of production volumes, up to a series of 250L bioreactors.